Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial
OBJECTIVE: A randomized controlled trial was conducted to determine whether 7 days of intravenous eflornithine (100 mg/kg every 6 h) was as effective as the standard 14-day regimen in the treatment of late-stage Trypanosoma brucei gambiense trypanosomiasis. METHODS: A total of 321 patients (274 new...
Saved in:
Main Authors: | Jacques Pépin (Author), Nzambi Khonde (Author), Faustine Maiso (Author), Félix Doua (Author), Shabbar Jaffar (Author), Stéphane Ngampo (Author), Bokelo Mpia (Author), Dawson Mbulamberi (Author), Felix Kuzoe (Author) |
---|---|
Format: | Book |
Published: |
The World Health Organization,
2000-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo
by: Manica Balasegaram, et al.
Published: (2006) -
Gambian human African trypanosomiasis in North West Uganda. Are we on course for the 2020 target?
by: Richard Selby, et al.
Published: (2019) -
Enantiospecific antitrypanosomal in vitro activity of eflornithine.
by: Mikael Boberg, et al.
Published: (2021) -
Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study
by: Victor Kande Betu Ku Mesu, DPH, et al.
Published: (2021) -
Identification of transport systems involved in eflornithine delivery across the blood-brain barrier
by: Christopher P. Watson, et al.
Published: (2023)